Hepion Pharmaceuticals, Inc. filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of Delaware on October 1, 2026. The filing became effective immediately upon submission. The primary purpose of the amendment is to increase the authorized number of shares of the Company’s common stock.
Under the terms of the amendment, the authorized number of shares of common stock has been raised to 750,000,000. Previously, the authorized share count was lower; the filing indicates this specific increase was the only material change made to the corporate charter through this amendment.
The Company is incorporated in Delaware and is listed under the trading symbol HEPA on the OTC QB market. The filing was signed by Gary Stetz, the Interim Chief Executive Officer, on October 2, 2026.
